📊 PTCT Key Takeaways
Is Ptc Therapeutics, Inc.. (PTCT) a Good Investment?
PTC Therapeutics demonstrates exceptional operational performance with 114.5% revenue growth and exceptional profitability margins (50.1% operating, 39.4% net), supported by strong free cash flow of $702.3M. However, the company carries a critical balance sheet vulnerability with negative stockholders' equity of -$205.3M (liabilities exceed assets), and paradoxically shows flat net income growth despite doubling revenues, raising concerns about margin sustainability and underlying financial stress despite positive cash generation.
Why Buy Ptc Therapeutics, Inc.. Stock? PTCT Key Strengths
- Exceptional revenue growth of 114.5% YoY demonstrates strong market demand and commercial execution
- Excellent profitability margins: 50.1% operating margin and 39.4% net margin indicate pricing power and operational efficiency
- Robust free cash flow of $702.3M (40.6% FCF margin) provides financial flexibility and strong debt service capacity despite balance sheet concerns
- Healthy liquidity with $984.6M cash on hand and current ratio of 2.35x supporting operations
PTCT Stock Risks: Ptc Therapeutics, Inc.. Investment Risks
- Critical: Negative stockholders' equity of -$205.3M indicates balance sheet is technically insolvent; total liabilities ($3.1B) exceed total assets ($2.9B)
- Paradoxical: Net income flat YoY (0% growth) despite 114.5% revenue growth suggests significant margin compression, one-time charges, or operational headwinds masking operational performance
- Unsustainable capital structure: Heavy leverage relative to equity base creates financial distress risk if operating performance deteriorates or refinancing conditions worsen
Key Metrics to Watch
- Trend in stockholders' equity and deleveraging progress; path to positive equity
- Net income growth trajectory and gross margin trends to assess sustainability of profitability
- Operating cash flow stability and capital structure changes (debt issuance, equity raises, share buybacks)
Ptc Therapeutics, Inc.. (PTCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 40.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.35x current ratio provides a solid financial cushion.
PTCT Profit Margin, ROE & Profitability Analysis
PTCT vs Healthcare Sector: How Ptc Therapeutics, Inc.. Compares
How Ptc Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ptc Therapeutics, Inc.. Stock Overvalued? PTCT Valuation Analysis 2026
Based on fundamental analysis, Ptc Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ptc Therapeutics, Inc.. Balance Sheet: PTCT Debt, Cash & Liquidity
PTCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ptc Therapeutics, Inc..'s revenue has grown significantly by 221% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.37 indicates the company is currently unprofitable.
PTCT Revenue Growth, EPS Growth & YoY Performance
PTCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $196.8M | $15.9M | $0.20 |
| Q2 2025 | $178.9M | -$64.8M | $-0.83 |
| Q1 2025 | $210.1M | -$91.6M | $-1.20 |
| Q3 2024 | $196.6M | -$106.7M | $-1.39 |
| Q2 2024 | $186.7M | -$99.2M | $-1.29 |
| Q1 2024 | $210.1M | -$91.6M | $-1.20 |
| Q3 2023 | $196.6M | -$109.3M | $-1.53 |
| Q2 2023 | $165.5M | -$152.1M | $-2.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ptc Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PTCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ptc Therapeutics, Inc.. (CIK: 0001070081)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_050401.xml | View → |
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_050401.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_050402.xml | View → |
| Mar 26, 2026 | 4 | xslF345X06/form4-03262026_110330.xml | View → |
| Mar 25, 2026 | 8-K | tmb-20260324x8k.htm | View → |
❓ Frequently Asked Questions about PTCT
What is the AI rating for PTCT?
Ptc Therapeutics, Inc.. (PTCT) has an AI rating of HOLD with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTCT's key strengths?
Claude: Exceptional revenue growth of 114.5% YoY demonstrates strong market demand and commercial execution. Excellent profitability margins: 50.1% operating margin and 39.4% net margin indicate pricing power and operational efficiency.
What are the risks of investing in PTCT?
Claude: Critical: Negative stockholders' equity of -$205.3M indicates balance sheet is technically insolvent; total liabilities ($3.1B) exceed total assets ($2.9B). Paradoxical: Net income flat YoY (0% growth) despite 114.5% revenue growth suggests significant margin compression, one-time charges, or operational headwinds masking operational performance.
What is PTCT's revenue and growth?
Ptc Therapeutics, Inc.. reported revenue of $1.7B.
Does PTCT pay dividends?
Ptc Therapeutics, Inc.. does not currently pay dividends.
Where can I find PTCT SEC filings?
Official SEC filings for Ptc Therapeutics, Inc.. (CIK: 0001070081) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTCT's EPS?
Ptc Therapeutics, Inc.. has a diluted EPS of $7.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PTCT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ptc Therapeutics, Inc.. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PTCT stock overvalued or undervalued?
Valuation metrics for PTCT: ROE of N/A (sector avg: 15%), net margin of 39.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PTCT stock in 2026?
Our dual AI analysis gives Ptc Therapeutics, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PTCT's free cash flow?
Ptc Therapeutics, Inc..'s operating cash flow is $711.2M, with capital expenditures of $8.9M. FCF margin is 40.6%.
How does PTCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 39.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.35 (avg: 2).